Maverick Therapeutics is now part of Takeda. Follow us at https://www.linkedin.com/company/takeda-pharmaceuticals/ Maverick Therapeutics is pioneering the next generation of redirected T-cell targeted immunotherapies. Maverick’s highly innovative platform, COBRA™, is the most advanced bispecific T-cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.
